Back to Search
Start Over
Ledipasvir‐Sofosbuvir for 12 Weeks in Children 3 to <6 Years Old With Chronic Hepatitis C
- Source :
- Hepatology (Baltimore, Md.)
- Publication Year :
- 2019
- Publisher :
- Ovid Technologies (Wolters Kluwer Health), 2019.
-
Abstract
- For children under 12 years of age who have chronic hepatitis C virus (HCV) infection, there are currently no approved treatments with direct‐acting antiviral agents. We therefore evaluated the safety and efficacy of ledipasvir‐sofosbuvir in HCV‐infected children aged 3 to
- Subjects :
- Male
0301 basic medicine
medicine.medical_specialty
Time Factors
Cirrhosis
Sustained Virologic Response
Sofosbuvir
Viral Hepatitis
Antiviral Agents
03 medical and health sciences
0302 clinical medicine
Pharmacokinetics
Internal medicine
medicine
Clinical endpoint
Humans
Child
Adverse effect
Fluorenes
Hepatology
business.industry
Original Articles
Hepatitis C
Hepatitis C, Chronic
medicine.disease
Treatment Outcome
030104 developmental biology
Child, Preschool
Hepatocellular carcinoma
Vomiting
Original Article
Benzimidazoles
Female
030211 gastroenterology & hepatology
medicine.symptom
Uridine Monophosphate
business
medicine.drug
Subjects
Details
- ISSN :
- 15273350 and 02709139
- Volume :
- 71
- Database :
- OpenAIRE
- Journal :
- Hepatology
- Accession number :
- edsair.doi.dedup.....13051bc4a2aee8381cb1a24e041b05d5